Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

A. Craig Lockhart,Yongjian Liu,Farrokh Dehdashti,Richard Laforest,Joel Picus,Jennifer Frye,Lauren Trull,Stefanie Belanger,Madhuri Desai,Syed Mahmood,Jeanne Mendell,Michael J. Welch,Barry A. Siegel

Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

2016

A. Craig Lockhart
Yongjian Liu
Farrokh Dehdashti
Richard Laforest
Joel Picus
Jennifer Frye
Lauren Trull
Stefanie Belanger
Madhuri Desai
Syed Mahmood
Jeanne Mendell
Michael J. Welch
Barry A. Siegel

Purpose The purpose of this study was to evaluate the safety, dosimetry, and apparent receptor occupancy (RO) of [64Cu]DOTA-patritumab, a radiolabeled monoclonal antibody directed against HER3/ERBB3 in subjects with advanced solid tumors.

Keywords:

Medicine
Nuclear medicine
Positron emission tomography
PET-CT
DOTA
Dosimetry
Patritumab
Monoclonal antibody
Receptor
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations